Study to Assess the Efficacy of Cognitex

NCT00719953 | Completed Phase 4 Results

• 2 other identifiers: TASMC-08-NV-305-CTIL0305-08-TLV
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

A Single-Center, Open Label Study to Assess the Efficacy of Cognitex in Elderly Subjects with Memory Impairment

Conditions

Elderly; Memory Impairment

Keywords

Cognitex; subjects

Outcome Measures

Primary Outcomes (1)

• Improvement of Cognitive Performance (Change From Baseline in Neuropsychological Computerized Test)

  The computerized neuropsychological assessment software consists of seven separate tasks: symbol spotting, pattern identification, pattern recall, digit-symbol substitution, digits span forward, digits span backward and delayed pattern recall. Based on the results obtained in the single tasks, eight cognitive composite scores are calculated including focused attention, sustained attention, memory recognition \& recall, visuospatial learning, spatial short term memory, executive functions and mental flexibility.The total score range is from 0 to 100 points(0 is worse, 100 is best).

  Base line and 12 weeks

Interventions

Cognitex DIETARY_SUPPLEMENT

Treatment will consist of one capsule of Cognitex (Life Extension, USA), three times a day, with meals, delivering a total of 600 mg GPC, 100 mg PS-omega 3, 20 mg vinpocetine, 50 mg uridine-5'-monophosphate (disodium), 550 mg plant extracts (150 mg wild blueberry, 125 mg ashwagandha, 150 mg grape seed, 125 mg hops, ginger and rosemary). Duration: 15 weeks

Eligibility Criteria

• Age: 60 Years - 90 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Ability to give written informed consent.
• Age: 90≥ years ≥60.
• Gender: male and female.
• Memory test performance within or below the mean established for adults in the computerized cognitive tool, with a maximum of four neuropsychological subtests scored 1.5 SD above the mean.
• Language: Subjects must be able to read, write and speak Hebrew.
• Ability to perform tests and interviews.

You may not qualify if:

• Evidence of delirium, confusion, or other disturbances of consciousness.
• Evidence of dementia.
• Any Neurological disorder that could produce cognitive deterioration. Such disorders include Parkinson's disease, stroke, intracranial hemorrhage, local brain lesions including tumors and normal pressure hydrocephalus.
• History of any infective or inflammatory brain disease including those of viral, fungal, or syphilitic etiologies.
• Head injury immediately preceding cognitive deterioration.
• Evidence of depression as determined by a the Geriatric Depression Scale (short version) score of 5 or more.
• Current diagnosis or history of alcoholism or drug dependence.
• Any medical disorder that could produce cognitive deterioration including renal, respiratory, cardiac, and hepatic disease, diabetes mellitus, endocrine, metabolic or hematological disturbances unless well controlled, and malignancy not in remission for more than two years
• Use of anti-clotting or antiplatelet medications or supplements for less than two years.
• History of clotting or platelet disorder unless well controlled.
• Use of any supplement that may significantly affect cognitive functioning during the month prior to study initiation.
• Use of any experimental medication within 1 month prior to screening or as concomitant medications.
• History of hypersensitivity or allergy to soy or fish.

Sponsors & Collaborators

• Tel-Aviv Sourasky Medical Center: lead
• Enzymotec: collaborator

Study Sites (1)

Suorasky Medical Center

Tel Aviv, Israel

Location

Related Publications (1)

• Richter Y, Herzog Y, Eyal I, Cohen T. Cognitex supplementation in elderly adults with memory complaints: an uncontrolled open label trial. J Diet Suppl. 2011 Jun;8(2):158-68. doi: 10.3109/19390211.2011.569514.

  PMID: 22432687 DERIVED

MeSH Terms

Conditions

Memory Disorders

Condition Hierarchy (Ancestors)

Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: Professor N. Vaisman
• Organization: Sourazky Tel-Aviv Medical Center

vaisman@tasmc.health.gov.il

972-3-6974807

Study Officials

• Nachum Vaisman, Professor

  Tel-Aviv Sourasky Medical Center, Israel

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER GOV

Study Record Dates

• First Submitted: July 21, 2008
• First Posted: July 22, 2008
• Study Start: August 1, 2008
• Primary Completion: March 1, 2009
• Study Completion: August 1, 2009
• Last Updated: April 20, 2010
• Results First Posted: February 4, 2010

Record last verified: 2008-07

Locations

IL (1)